MAPK3 and non-small cell lung carcinoma: Certain studies show that either treatment with ephrin-A1-Fc or EphA2 knockdown in NSCLC (Non-Small Cell Lung Cancer) cells lowers cell proliferation and migration in vitro mainly through reduced S897 phosphorylation and downregulation of ERK1/2 (Extracellular signal-Regulated Kinase 1/2) activity [103,122,123,124].